Retatrutide Dosage Schedules: What the Trials Used

The short version

Retatrutide dosage information on this page is reported as trial design fact — what researchers administered to which population at which amount and schedule, and what they found. This is not a dosing guide. Retatrutide is investigational, not approved, and there is no labeled dose.

The core dosing pattern across Phase 2 trials: subcutaneous injection (injected into the fatty layer under the skin) once weekly, starting at a low amount and escalating gradually to allow the body to adapt to GI side effects. The Phase 2 obesity trial tested 1 mg, 4 mg, 8 mg, and 12 mg weekly doses. Phase 1b used an ascending sequence starting at 0.5 mg and stepping up to 12 mg. The ~6-day half-life of retatrutide — how long it takes for half the compound to clear the blood — is what makes once-weekly dosing possible.

Full pharmacokinetics are on the retatrutide half life page.

Retatrutide dosage

Trial doses studied in humans ^[1][2][4]:

Phase 1b (12 weeks, type 2 diabetes adults, n=72): 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg subcutaneous once weekly. The ascending sequences (3/6 and 3/6/9/12 mg) represent titration steps — participants started at the lower amount and escalated to the next level on a defined schedule.

Phase 2 obesity (48 weeks, adults with obesity, n=338): Fixed doses of 1, 4, 8, or 12 mg subcutaneous once weekly. All doses were initiated at a starting level and escalated within each arm over multiple weeks.

Phase 2 type 2 diabetes (36 weeks, n=281): 0.5 mg escalating to 12 mg subcutaneous once weekly in stepwise increments.

The dose-response relationship in Phase 2 obesity was steep: -8.7% (1 mg), -17.3% (4 mg), -22.8% (8 mg), -24.2% (12 mg) body-weight change versus -2.1% for placebo ^[1].

Dose escalation is not optional in trial design — it is the primary strategy for managing GI adverse events. Reviews confirm that slow up-titration reduces nausea burden across the GLP-1 class ^[7].

Retatrutide side effects in dose context

Adverse events from the Phase 2 obesity trial were dose-related ^[1]:

• Nausea: affected ~23% at 1 mg, rising to ~45% at 12 mg.
• Vomiting: 12–28% across the dose range.
• Diarrhea: 12–20%.
• Constipation: 12–22%.
• Discontinuations due to AEs: 3% (1 mg) to 18% (12 mg).
• Heart-rate increase: dose-dependent, peaking at ~24 weeks; mean increase ~5–7 bpm at highest doses.
• Injection-site reactions: ~8%.

No severe hypoglycemia. No deaths in the Phase 2 program. GI events were mostly mild-moderate and improved with time in participants who stayed in the trial.

For the community signal data — what people using research-labeled retatrutide outside trials report — see Retatrutide effects.

How to reconstitute retatrutide

This is a common search question. The direct answer: there is no approved reconstitution protocol for retatrutide. In Phase 2 and Phase 3 trials, retatrutide was supplied as a pre-formulated single-use prefilled pen or syringe by the manufacturer (Eli Lilly) under clinical-trial GMP (good manufacturing practice) conditions. Participants did not reconstitute it themselves.

The stability note from the compound record: retatrutide was studied only as a clinical-trial investigational product administered by once-weekly subcutaneous injection. No approved formulation, storage temperature, diluent specification, or reconstitution standard exists for any non-trial preparation.

Gray-market research-labeled retatrutide typically arrives as a lyophilized (freeze-dried) powder. Any reconstitution instruction circulating for such products is not derived from approved labeling — it does not exist. It is community convention applied to an unregulated, unverified product.

Retatrutide availability

Retatrutide is not commercially available. It is not a prescription drug. There is no approved indication and no regulatory approval in any country as of mid-2026.

Access pathways that currently exist:

1. Clinical trial enrollment — TRIUMPH Phase 3 trials are enrolling eligible participants in multiple countries. ClinicalTrials.gov lists active sites.
2. Gray-market research-labeled material — unregulated, unverified, and outside any clinical oversight. Identity, purity, and sterility cannot be confirmed.

There is no third option.

When will retatrutide be available

No regulatory filing date has been announced by Eli Lilly as of mid-2026. Phase 3 TRIUMPH trials are running. Regulatory submission typically requires completed Phase 3 data plus a full manufacturing and safety package — a process that, for a novel drug, takes a minimum of one to three years after trial completion.

The earliest realistic scenario for a retatrutide approval in the United States would be late 2026 to 2027, assuming trial completion and rapid regulatory review — neither of which is guaranteed. Phase 3 trial completion dates listed on ClinicalTrials.gov (NCT05929066, NCT05931367, NCT06383390) are the authoritative public estimate source.